BeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by Marshall Wace LLP

Marshall Wace LLP lowered its position in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 50.2% in the second quarter, HoldingsChannel.com reports. The firm owned 51,987 shares of the company’s stock after selling 52,428 shares during the quarter. Marshall Wace LLP’s holdings in BeiGene were worth $7,417,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Sei Investments Co. lifted its holdings in BeiGene by 3.6% during the 2nd quarter. Sei Investments Co. now owns 24,248 shares of the company’s stock worth $3,459,000 after buying an additional 848 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in BeiGene by 118.9% during the second quarter. Dimensional Fund Advisors LP now owns 11,499 shares of the company’s stock worth $1,649,000 after purchasing an additional 6,246 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in BeiGene by 48.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 26,924 shares of the company’s stock valued at $3,841,000 after purchasing an additional 8,800 shares in the last quarter. Barings LLC boosted its holdings in BeiGene by 66.4% in the second quarter. Barings LLC now owns 51,763 shares of the company’s stock valued at $7,385,000 after purchasing an additional 20,663 shares in the last quarter. Finally, Headlands Technologies LLC increased its stake in BeiGene by 761.2% in the second quarter. Headlands Technologies LLC now owns 2,773 shares of the company’s stock valued at $396,000 after purchasing an additional 2,451 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Price Performance

Shares of NASDAQ:BGNE opened at $224.51 on Tuesday. BeiGene, Ltd. has a one year low of $126.97 and a one year high of $237.10. The stock has a market capitalization of $21.76 billion, a price-to-earnings ratio of -29.66 and a beta of 0.61. The company has a 50-day simple moving average of $187.99 and a 200-day simple moving average of $166.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.27) by $1.12. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The firm had revenue of $929.20 million for the quarter, compared to analysts’ expectations of $810.34 million. During the same quarter in the previous year, the firm posted ($3.64) EPS. The firm’s revenue for the quarter was up 56.1% on a year-over-year basis. On average, analysts predict that BeiGene, Ltd. will post -5.13 EPS for the current year.

Insider Activity

In related news, COO Xiaobin Wu sold 4,500 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $200.14, for a total transaction of $900,630.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other BeiGene news, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total value of $26,021.78. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Xiaobin Wu sold 4,500 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $200.14, for a total value of $900,630.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,527 shares of company stock valued at $2,214,263. Company insiders own 7.43% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BGNE shares. JPMorgan Chase & Co. boosted their price objective on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Citigroup boosted their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. JMP Securities began coverage on BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective on the stock. Finally, Bank of America reduced their target price on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a report on Tuesday, July 9th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $241.21.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.